Current Hematologic Malignancy Reports

Papers
(The TQCC of Current Hematologic Malignancy Reports is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Financial Toxicity in Patients with Hematologic Malignancies: a Review and Need for Interventions99
Monoclonal Gammopathy-Associated Neuropathy28
Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations27
Management of Chronic Myeloid Leukemia in Children and Young Adults24
Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease19
Correction to: Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities17
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications17
Telomere Biology Disorder: A Focus on Gastrointestinal and Hepatic Manifestations16
Treatment-Free Remission: the New Goal in CML Therapy16
Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer14
Value in Myeloma Care: Myth or Reality14
Transplantation and Cellular Therapy for Older Adults—The MSK Approach13
Targeting Apoptosis in ALL13
Challenges in Chronic Myeloid Leukemia Management in South America13
Acute Lymphoblastic Leukemia and Acute Lymphoblastic Lymphoma: Same Disease Spectrum but Two Distinct Diagnoses12
Prognostic and Predictive Models in Myelofibrosis12
Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic12
Multidisciplinary Approach to Older Adults with Hematologic Malignancies—a Paradigm Shift12
New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications11
Diagnosis and Management of Pulmonary Manifestations of Telomere Biology Disorders11
Multiple Myeloma: Current Clinical Landscape and Compounding Costs10
How Do We Manage Chronic Lymphocytic Leukemia in India10
The Evolving Landscape of Frontline Therapy in Chronic Phase Chronic Myeloid Leukemia (CML)10
Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies10
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia9
Progress and Challenges in Survivorship After Acute Myeloid Leukemia in Adults9
Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions9
Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia8
Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies8
A Multi-disciplinary Approach to Managing Chronic Myelogenous Leukemia Patients on Oral Anticancer Therapy at a Large Academic Medical Center8
0.048366069793701